Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Prior, C; Oroszy, S; Oberaigner, W; Ambrosch, G; Mohn-Staudner, A; Pfeifer, W; Pirker, R; Huber, H.
Advanced non-small-cell lung cancer: adjunctive interferon gamma in induction and maintenance therapy.
J Cancer Res Clin Oncol. 1999; 125(1):42-46
Doi: 10.1007%2Fs004320050240
Web of Science
PubMed
FullText
FullText_MUG
- Autor*innen der Med Uni Graz:
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- PURPOSE: To evaluate the feasibility of interferon gamma (IFNgamma) as an adjunct to chemotherapy in advanced non-small-cell lung cancer (NSCLC). METHODS: A total of 32 patients were recruited and received 25 mg/m2 cisplatin and 100 mg/m2 etoposide on days 8, 10 and 12 every 3 weeks for a total of three cycles. A dose of 100 microg IFNgamma was given subcutaneously three times weekly from days 1 to 8 and between days 15 and 29. After induction, all patients except those with progressive disease were offered IFNgamma maintenance therapy: 100 microg three times weekly. RESULTS: The following responses were obtained: partial response, 5 (16%); minor response, 12 (37%); stable disease, 4 (13%); progressive disease, 11 (34%). The survival rates after 1 and 2 years were 47% and 25% respectively. Patients receiving maintenance IFNgamma had a 2-year survival rate of 58%. Toxic side-effects were rare and included grade III/IV fever (7%/1%) and grade III/IV leucopenia (4%/1%). CONCLUSIONS: In patients with advanced NSCLC, an adjunctive dose of 100 microg IFNgamma, given three times weekly in the induction and maintenance phase, is feasible. Survival data seem favourable so this regimen may warrant further investigation in a phase III study.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - administration and dosage
- Bone Neoplasms - drug therapy
- Carcinoma, Non-Small-Cell Lung - complications
- Cisplatin - administration and dosage
- Disease Progression - administration and dosage
- Etoposide - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Interferon Type II - administration and dosage
- Leukopenia - complications
- Lung Neoplasms - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Survival Rate - drug therapy
- Treatment Outcome - drug therapy
- Vinblastine - analogs and derivatives
- Find related publications in this database (Keywords)
- Non-Small-Cell Lung Cancer
- Chemotherapy Interferon Gamma
- Phase II Study